Reference number(s)
1932-A

SPECIALTY GUIDELINE MANAGEMENT

JEVTANA (cabazitaxel)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
Jevtana is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Compendial Use
1. Second-line or subsequent treatment for castration-resistant distant metastatic disease previously treated with a docetaxel-based regimen or in patients who are not candidates for, or are intolerant of docetaxel
2. Subsequent treatment for castration-resistant distant metastatic disease previously treated with enzalutamide (Xtandi) or abiraterone (Zytiga)

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Metastatic castration-resistant prostate cancer (CRPC)
Authorization of 6 months may be granted for the treatment of metastatic castration-resistant prostate cancer when previously treated with any of the following:
A. A docetaxel-containing regimen or in patients who are not candidates for or who are intolerant to docetaxel
B. Enzalutamide (Xtandi)
C. Abiraterone (Zytiga)

III. CONTINUATION OF THERAPY

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

IV. REFERENCES

1. Jevtana [package insert]. Bridgewater, NJ: sanofi-aventis; February 2021.
2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed July 6, 2021.